newsfilter
← Latest News
Earnings Call Transcripts·

Inhibikase Therapeutics, Inc. at Jefferies Global Healthcare Conference in London - INHIBIKASE THERAPEUTICS INC

Hi, good afternoon, and welcome to the Jefferies Healthcare Conference in London. My name is Dennis Dink, biotech analyst here. I have the great pleasure of having Indivacase Therapeutics here. We have the CEO, Mark Iwiki. Welcome. Thank you very much, Dennis. Great to be here. So before we kind of go into more about the business and some of the progress you guys have made, maybe talk a little bit high level around the company and what you guys Have done this year and what, you know, what you guys are looking forward to. Yeah, this has been a super exciting year for Inhibicase. We kicked off a phase three program. We have 28 countries approved and 79 sites up and running. And that's really in the past kind of four to six months. So we're feeling great. We're achieving our internal expectations. There's been a tremendous amount of excitement from thought leaders, investigators, practicing physicians about the promise of imatinib. You know, most people know that imatinib had been studied before in the IMPRESS trial by Novartis and had always felt like this would be a great product to bring to the market. I think in general, too, what you're seeing is antiproliferatives are of tremendous interest. Of course, the Tadracep is off to a great start in the U.S. and approved in many other countries. And I think it's really opening up the market that these products alone and in combination in the future will really be the next standard of care. Sure. So maybe talk a little bit more about PAEH and just how that landscape is changing with cetatercept and then just some of the other therapeutics that may be, you know, that are in development and could be approved in the next few years. You know, it was dominated by vasodilators for 20 years, 30 years, and those products are great and they're needed and they'RE important, but they'RE limited in a way in their ability to really change the long-term course of the disease. Cetatercep, an active in-trap product, is an antiproliferative agent. And our product, a kinase inhibitor, IKT001, which is going to deliver imatinib, is also an anteproliferated agent. And that is really changing, I think, the framing of the disease and how it's going to be treated. We've already seen a bit of a downstreaming of Cetetercep into the more moderate populations. And I think when you talk with the thought leaders, they are most excited about getting these products used earlier and earlier in the course of the disease. I think another piece of it, and we always get asked this question, well, does the market need multiple anti-proliferative agents? And the question or the answer to that is unequivocally yes. It needs no single drug is going to be able to treat this disease. There's still going to быть combination therapy used routinely. In fact, I think what we're going to see in the future is combinations of antiproliferatives used, and you'll see some of the more complicated vasodilator products will be pushed to kind of last line, and I think you're goingto see these antipoliferative agents kind of be second-line therapy, and maybe even over time they'll be beginning, you know, part of a starting regimen. Sure. Okay, so you guys are in Phase 3 that's enrolling, and you guys will have a number of updates in 27, 28, and 29. So just remind us what those are and maybe go into a little bit more detail around some of the safety updates that you guys will have next year. Yeah. So in 2027, what we've communicated is that we will provide what we call a safety update. And that's going to look a lot like what other people have done during the blinded portion of a study. So what we are obligated to do for a financing tranche is to have 50 patients into the study and 12 weeks' worth of data. The obligation we have is just to report out that the DSMB has looked at that data and that the trial can continue, and we believe that that's probably the limit to the information that we'll provide. But what it will clearly do is show that we're executing well and that trial is on track. And then a really exciting readout for us is mid-2028. That is the Part A of our study, which is 140 patients with a primary endpoint of PVR. It often looks like a phase two study for other development programs. For us, we call that part A, and that will be a full data set. So PVR is how it's powered in the primary endpoint. We'll have six-minute walk data. We'llhave other secondary endpoint data, so we're really excited about that. And then the pivotal data comes in mid-29. So think of it as first half 27 for a safety update, studies on track, enrolling nicely, mid-28, a pretty definitive data set, with PVR being a highlight there, and then mid-29, that pivotal data that we'll be able to file upon. And our program is pretty interesting in a way, because what we've done is have a Part A and a Part B, but we use the same sites. So as soon as the last patient is enrolled in Part A, the next patient goes right into Part B, and that will give us two independent data sets and hopefully a really good package for filing. So for the safety update next year, 50 patients worth of data, 12 weeks of follow-up, but you also said limited disclosure. So, like, I guess help us understand what exactly the DSMV is looking, what will be communicated to you, and could, you know, could you guys look at perhaps blinded PVR at that point? Yeah, look, I, I guest the answer to that question is we could certainly look at everything but because it's such a small data set right just 50 patients right in principle 25 on drug 25 on on placebo we're likely to just stick with what we're obligated to do that brings in a 55 million dollar financing for us just to be able to have the dsmb say that you know there are no meaningful issues that would make them want to stop the trial and that the trial could continue it's very fair for everyone to ask investors analysts you know you'll have more data could you report, you know, blinded information. Of course, we will have that data, but we think we'll just stick to the requirement that we have in the financing. Okay. Maybe I'll push on that a little bit more. Sure. Like the blinded, blind to PBR, I feel like it's fairly definitive because you don't really have a placebo response on PBR. Right. So, so you could like maybe for minus Does the DSMB have access to patient-level data? Do you have access to it even on a blind attraction? You know, of course, somewhere within the organization, but, you know, not the full management team or anything like that. We are not looking at that data day-to-day. And, you know, again, I think the tricky part is such a small it's only 25 patients on drug, 25 patients on placebo. So I think that's the real tricky. And it's only 12 weeks it's only half the study the study is 24 weeks so we're not trying to uh in any way like not want to disclose things but i i think we'll probably stick with the high level disclosure at this point so then once we're in 2028 and you guys will disclose the pbr data i guess what should people expect should they look at the impressed data and expect something similar or do you think that that's not the case no i that listen that's a great question what we've done is we made a pro drug of imatinib that uh you know stays intact in the gi tract to get a lot of benefits, and maybe we'll talk about that. But once it's converted in the plasma, it turns right into imatinib. And so we do expect to have imatiniblike efficacy. You know, I think most people would say that clinically meaningful difference in PVR would be like a 20% reduction in six-minute walk, maybe a 20-meter improvement. Of course, in IMPRESS, it was more like a 30% reduction and a 30-meter improvement in six-minute walk. And, you know, we do fully expect to be able to replicate that level of efficacy. Okay. Can you remind us, because IMPRESS was a very old study, right? So how has the treatment paradigm changed such that, you knows, patients today in a modern PAH trial, should we expect that same level of advocacy that we saw years ago from the press? It's a good question. Look, I think in principle, we are setting up our inclusion exclusion criteria to be able to get PVRs kind of in the mid 700s. And I think what you've seen in some modern studies that have been done with various products, including with imatinib by Alexander Rothman in his study, is that you're getting, you know, even in that study where most people were on the equivalent of 200 milligrams, which would be the lower dose of imatinab, there a 24% reduction in TPR. So I know there's a lot said about, oh, well, don't you need a 1,000-dine baseline? And I don't think that's the case. We don't believe that you do. So will we be really happy if we meet those clinical thresholds that are in the market? Yes, and there have been lots of drugs approved on data like that. Do we have kind of high expectations and hopes for the drug and for the company that we can be more in that 30-ish range? We do, but I think anything in the 20% reduction and 20-meter improvement would tell us that we have a fantastic product. Okay, so just to be clear, what's clinically meaningful is 2020, essentially, right? But you guys feel good based off of the impressed data and the MOA that you could get to 30% PVR or 30-30. Yeah, those are our hopes and our expectations. That's right. Okay. Right. When you guys disclose the PBR data in 2028, would we also get a look at six-minute walk at that time? Yeah, we will have that data. It's not powered for that, so it's, you know, about half the size, the trial is about halfthe size as the Part B of the study, but we will certainly have that information, and we expect to share that with everyone. Okay. Can you comment on just the interpretability of that data, and also the fact that six-minutes walk, you know for placebo typically is quite noisy so so how are you going to manage some of that in the phase three yeah um well look uh the way that's managed in the phase three is certainly to increase the the n in the study right so i think 340 patients versus 140 is uh what we have decided at this point is what we're targeting for part b for the six minute walk we certainly can take a look at part A, and should we need, you know, a bigger sample size, we can do that as well. That's one of the benefits of breaking the study into two pieces. You know, I think fundamentally what we expect to be able to see is some trends. I think it'd be hard for us to think that we could get statistical significance with a smaller number of patients, but, you Know, we're certainly hoping and excited to see that data when it comes. Sure. Okay. You mentioned earlier IKT's MOA, right? And it's a pro-drug and you should get good efficacy, but talk about the safety component as well, because that was sort of an issue with Impress. Yeah, it's a great point. There were a lot of patients that discontinued because of really meaningful GI side effects. Sometimes I think we say that and you think, oh, it was just a little bit of a stomach ache or maybe some nausea this is debilitating nausea vomiting this is patients on imatinib you know not being able to leave the house and more importantly not being able to tolerate the 400 milligram dose so there's a couple of things here we designed a pro drug that's that pro drug that stays intact there's some real benefits of that right um c kit in the gi track as you could think of it almost as one of the most important um you know pacemakers of the GI system, right? So if you're inhibiting that, you're slowing down gastric emptying, you're causing a lot of nausea and vomiting. We've shown preclinically that we have a meaningfully different profile than imatinib does. In fact, imatinab looks a lot like morphine, right, and I don't have to educate anyone on the effects of morphine on the GI tract and nausea and vomiting, so we're seeing a very clean profile right now in the preclinkal studies. We have also done something else, which is we're doing a slow titration to get from our lower dose to the higher dose. And in PRESS, they move people from 200 to 400, so from the low dose to high dose in two weeks. We think that caused a lot of issues. When you talk to the investigators that were part of that study, they'd say that is one of the number one things that really caused issues for dropouts. So not only do we have what we would call kind of a GI protective pro-drug here for imatinib, but we're also going to take eight weeks to get them to the high dose. And we've got a 300 milligram dose, a 400 milligram dose and a 500 milligram dose. You can think of our 300 as being a little bit better than 200 or a little more drug, I should say. And our 500 milligram doses right around 383. So close to that 400 milligram. So I think the combination of those two things has us very optimistic that we're going to be able to get more people to the higher dose. The efficacy and the adverse events are certainly dose-related with imatinib. Okay. What is your level of confidence to get these patients up to the 500 milligram doses? Is it kind of like a forced titration, or is it kindof like PK-dependent, you know, like maybe you guys will do some PK sampling and things like that, like how should we think about patients reaching the target dose to get maximum efficacy? Yeah, I mean it's really up to the individual investigator and of course the patient, but we're encouraging all patients to go through the doses. Certainly if somehow they, you know can't tolerate it, we're not going to, you now, overly force people to get there and if they get to the 500 milligram dose and for some reason they can't tolerated, they're allowed to step down and this is all part of the procedures that we put in place so that we can keep people in the trial. We think the real key here is the design elements to make sure that we're not ending up with dropouts like they did in Impress, but rather we can find the right maximum dose for each patient. And maybe it's a good time to just point out that even the lower doses of imatinib have been shown multiple times to deliver 20% reductions in PVR and 20-meter improvements in six-minute walks. So while I'm expressing our desire to get to the higher doses, because I think that will deliver class-leading efficacy, efficacy that would look similar to what Cetatricep shown, there's certainly the lower doses that would make a great product for the vast majority of patients. Okay. In terms of safety, I guess, given the pro-drug and the novel formulation here, what do you expect to see in terms of nausea, vomiting, and GI distress? Yeah, look, I think we've shown pre-clinically that we have a much, much lower effect on that. Now, we have to conduct a clinical study here to see if that bears out in patients, but we're feeling, you know, pretty good about that. When it is converted to imatinib, because you're asking about safety, we're going to see those same kind of systemic side effects that you see with imatinab. So, you knows, edema and some other issues but doctors especially investigators in the clinical trial are well versed on how to handle edema practicing doctors are and for sure the investigators are yeah and i think that's a really important point around edema right because i believe when impress was run uh some of the investigators categorized edema as worsening of disease when it was in fact kind of on target so so what you're saying is the doctors uh the investigators that are part of your trial you've like they've kind of caught up with with uh with literature with how the moa works so that there wouldn't be some of this mischaracterization of edema that's a great way to say it dennis right the that trial ran to conclusion and it was really the the missing data and the dropouts that caused so so much of the problems for novartis to be able to get that that drug approved so i feel like we're really, you know, in a great place to be able to keep patients in the trial. And that last point you made is spot on. Some of that edema was seen as a clinical worsening event. We're going to great lengths to make sure that there's multiple classifications of what a clinical worsening even would have to be, not just the fact that someone got some edema. And of course, all throughout the protocol investigator training, we've been crystal clear about how that edemia should be managed, and really what the definition of a clinical worsening event will be. So we feel like we've learned a lot, and in addition, the medical community investigators have caught up with the best way to evaluate that. Sure. So right now you guys are focused in PAH, but talk about the opportunities outside of PAH. Yeah, well, I mean, put very simply, right, this anti-proliferative mechanism of action could be very valuable in group two, could be Very valuable in in group three perhaps as well. You know, we're excited about those opportunities. We're going to do some preclinical studies to see if the mechanism, you know, makes sense. We are going to be doing that during 2027. So you asked earlier about like what are data readouts. So what we are trying to do, we understand that these trials take a lot of time, right? So we have the safety readout, then the part A, then the Part B. We released some pre-clinicle data in combination with Sotatercept this year. I think that was well received by the market because we are always ask that question, can you use it with Sotatercept? I think we're showing that we can. There have been three or four studies now that have shown a kinase inhibitor with SOTATERCEP provides additive or synergistic, you know, effect. And then hopefully next year we'll also produce some preclinical data that shows that the mechanism may be appropriate for group two or group three. Sure. One of your PEH competitors filed an NDA on sort of a mixed, you phase three. The FDA is supposed to accept the NDA in November, right? So what are you looking for in that update? What are you looking for in that whole regulatory review process so that you can apply it to your own future? Yeah, it's a great question. Look, we're always rooting for other companies and we're rooting for patients and doctors for sure. So I think in some ways you could think of it as a win-win, If it gets accepted and it's reviewed and even if it's approved on that data set, you have to come to the conclusion that the FDA has kind of widened the confidence interval for the set of data that is approvable, right? People can argue a lot about whether it will be or it won't be. I think that's not for us to say. But if it was approved on the data set I think it would be a good thing for us, right. So in the spirit of win-win, if it wasn't accepted or it wasn' approved, well then that would clearly put us in the number two position to get out there. I feel like we have a chance to produce a clinical profile that is really overall maybe as good or even better than Sotatercept. Not only do we think we'll be able to maintain the efficacy levels of imatinib, because again and it's just converted right into free imatinib, maybe in many ways improve on the safety and tolerability profile or at least the way it's perceived and managed. But, you know, in addition to that, we have an oral once a day, and that is a huge clinical utility benefit, right? We know from the typical prescribing physician now, like we talk a lot about investigators and thought leaders, but the majority of the prescriptions written are, you Know, the average PAH center or treating physician and the idea to have an oral once a day is a huge benefit. Yeah and maybe talk about you know once you guys get approved the commercial positioning of your product where would you most likely focus in terms of the initial targeted outreach? Yeah look I think initially with all of these products they get tried in the more severe patients we saw that with Sotatercept, you see it with almost all new mechanisms of action. What's been really encouraging, but it shows you how much of an unmet need is out there, as you're already seeing Sottercept be used in more moderate patients, and you're hearing doctors talk about that. When we show doctors the profile of our product, I think we have a chance to be used even earlier than they are, because it's oral once a day, and we do expect to have kind of a clinical profile that matches them, and maybe even from a safety standpoint, a product that has an even better profile. So look, over the long term, as I said in the beginning, I think we believe that a product like ours could be that second product that you're put on, right? Maybe it's a PDE5 and an ERA, and as soon as you need something more, the doctors are going to want an antiproliferative and an oral once a day antipoliferative with great efficacy and tolerability is a terrific choice for them i think in the longer term than that you know maybe five years six years seven years you may see doctors in difficult to treat patients just add an antiproliferative right to their starting regimen okay um maybe in the last couple minutes just remind us uh you know how much cash and runway you have uh but also importantly the ip you know if you can comment a little bit about that as well? Yeah, sure. So, you know, what we've said to the market is that we have enough runway to get through the trial. So think of that as sort of mid-2029 is when we said we'd finish the part B of the study. The IP is 2039 and then with use patents out to 2044. So we have a long runway in front of us it is not just a reformulation of a mat nib it is a new nce but we do have the benefit of being able to use the 505 b2 strategy and when we converted from sort of the sequential phase 2b and then a phase 3 program we actually shaved about three years off the time doing nda or the time to approval for everybody in the room today well that's kind of built in but that was a huge win a year ago okay um maybe in the last minute you know mark any sort closing remarks you know to investors as we think about the next 12 to 36 months well look i think for everyone in this room and investors around the world um the team is doing a great job right 28 countries and 79 sites we are up and running um we are i think meeting a huge unmet need in the market to have a second anti-proliferative you know come to the market one with a great clinical profile. We're really optimistic about what the data could look like. These trials, they take time. And we understand from an investor standpoint, you know, a year away or a year and a half away feels like a lot of time, but we're going to keep delivering data. 2027, we have that safety, you knows, readout disclosure. And then mid-2028, the PVR data. That PVR data has been a huge catalyst for almost every company that's produced great data and then the pivotal date in 2029 and all along the way we're going to keep producing pre-clinical data for additional indications so we're super excited about the product team is doing a great job and you know hopefully as we get closer and closer the market will really appreciate that perfect well thank you so much mark for uh for being here thank you thank you Thank you.

Company
INHIBIKASE THERAPEUTICS INC
Keywords
INHIBIKASE THERAPEUTICS INC